BRCA1 and hepatocellular carcinoma: Cell lines harboring mutations in BRCA2 (MDA-MB-361, ZR75-30 or BT-20 with missense substitutions and BT-474 or HCC-1395 with nonsense mutations) or BRCA1 (HCC1954 with frameshift deletion according to COSMIC) showed sensitivity to treatment with abemaciclib (Supplementary Figure 3).